Language:
Instant News and Commentaries
2026-08-28
16:43
Zoomlion Reports 9.2% Revenue Growth in H1 2026, with International Revenue Up 12.5%

CHANGSHA, China, Aug. 28, 2026 /PRNewswire/ -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion") reported revenue of RMB 27.14 billion (approx. US$4.04 billion) for the first half of 2026, up 9.17% year over year, with revenue increasing in both domestic and international markets. International revenue rose 12.45% to RMB 15.54 billion (approx. US$2.31 billion), accounting for 57.25% of total revenue, while net cash generated from operating activities increased 38.12% to RMB 2.42 billion (approx. US$360.1 million).

The headquarters building at Zoomlion Smart City
The headquarters building at Zoomlion Smart City

International Business Sustains Growth as Local Capabilities Deepen

International business remained a major growth driver, with its share of total revenue rising 1.67 percentage points year over year to 57.25%. Through an end-to-end, digital and localized operating model, Zoomlion continued to deepen its presence in international markets. Growth in South America, Europe, Southeast Asia, Africa and East Asia exceeded the company's overall international growth rate.

Zoomlion strengthened local sales, service and supply capabilities across Europe, South America, Africa, Australia and New Zealand. As of June 30, it had more than 30 primary business hubs, over 530 secondary and tertiary outlets, more than 300 spare parts warehouses, and nearly 7,000 local employees worldwide.

Its Hungarian aerial work platform factory began production, while its German facility was expanded and upgraded into a multipurpose hub. The company also strengthened its international management and digital systems, improving responsiveness around the clock and oversight across sales opportunities, business execution and risk monitoring.

Diversified Portfolio Creates Additional Growth Drivers

Zoomlion maintained solid positions in its core concrete and crane machinery businesses. It advanced the rollout of electric products and premium equipment such as large mixing plants and long boom pump trucks, deepened collaboration with its Italian subsidiary CIFA, continued batch deliveries of large tonnage cranes, and made progress in wind power tower cranes and premium international segments.

Zoomlion's earthmoving, mining, aerial work platform and agricultural machinery businesses generated combined revenue of approximately RMB 12.5 billion (approx. US$1.86 billion), up about 10% and accounting for more than 46% of total revenue. Earthmoving machinery accounted for approximately 20% of revenue and became the largest contributor to Zoomlion's international revenue among its business segments.

Zoomlion also continued to advance electric and intelligent equipment across its portfolio, including electric construction machinery, new energy and autonomous mining equipment, and hybrid agricultural machinery. Several new energy mining products received EU CE certification, supporting their entry into international markets.

Zoomlion is also advancing embodied intelligence through its subsidiary, ZValley Technology Co., Ltd., which has developed several embodied AI robot products. Zoomlion has established capabilities spanning algorithms, software, hardware and industrial applications, supporting progress toward industrial deployment.

Industry trends, including infrastructure investment, equipment replacement and continued global capital spending on infrastructure and mining, are expected to support demand. Zoomlion will continue strengthening localized operations, diversifying its product portfolio and investing in technology to support sustainable, high-quality growth.

Information Provided by PR Newswire [Disclaimer]
16:35
HSI Adds 19 Pts for Day; BYD ELECTRONIC Leaps 6.3% Ahead of Results; OOIL Dives 8.7% Post-results; Z.AI and MINIMAX-W Subdued

On the Hong Kong stock futures settlement day, the HSI opened down 155 pts this morning (28th) before picking up. The index settled at 25,584, up 19 pts or 0.07% for the day, with total market turnover at HKD231.209 billion. The HSCEI closed at 8,490, up less than 1 pt. The HSTECH ended at 4,605, down 15 pts or 0.33%.

Among focus stocks, XIAOMI-W (01810.HK) climbed 1.24%; KUAISHOU-W (01024.HK) lost 0.59%; and BABA-W (09988.HK) dropped 1.39%. TENCENT (00700.HK) reversed early losses to gain 1.65% after Tencent Hunyuan released Hy4 preview. Blind tests showed the model slightly outperforming GLM 5.3 from Z.AI (02513.HK) and Kimi K3 from Moonshot AI. Hong Kong's two major AI model stocks came under pressure, with Z.AI plunging 6.03%, while MINIMAX-W (00100.HK) slid 4.51% after CICC lowered its TP.

For blue chips, OOIL (00316.HK) logged a nearly 24% decline in 1H profit, sending its share price down sharply by 8.65%, making it the worst-performing blue chip. SUNNY OPTICAL (02382.HK) soared 3.28% after results, supported by a TP uplift from Citi. LONGFOR GROUP (00960.HK) added 1.65% despite a 39% decline in 1H profit, while NONGFU SPRING (09633.HK) gained 1.3% after CMBI slightly raised its TP.

Lithium stocks rebounded. TIANQI LITHIUM (09696.HK) spiked 3.35% after 1H profit surged nearly 48x. GANFENGLITHIUM (01772.HK) hiked 1.17%, while CATL (03750.HK) edged up 0.49%. BYD ELECTRONIC (00285.HK), which was due to release results today, leapfrogged 6.27%, making it the best-performing blue chip.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
16:34
MINISO Group Announces 2026 June Quarter and Interim Unaudited Financial Results

Group Revenue Grew by 22.4% YoY in 26H1
MINISO Chinese Mainland Delivered 26.2% YoY Growth, the Highest First-half Growth Rate in Three Years, Powered by Mid-single Digit SSSG(1)
MINISO North America Delivered 37.0% YoY Revenue Growth, with Mid-single Digit SSSG(1)
Diluted Earnings Per ADS Grew by 8.2% YoY
Net Cash from Operating Activities Grew by 45.5% YoY
26H1 Returned RMB1,309.8 Million to Shareholders, Surpassing Adjusted Net Profit(2) Excluding FX(3)

GUANGZHOU, China, Aug. 28, 2026 /PRNewswire/ -- MINISO Group Holding Limited (NYSE: MNSO; HKEX: 9896) ("MINISO", "MINISO Group" or the "Company"), a global high-growth value retailer offering a variety of trendy lifestyle products featuring distinctive IP designs, today announced its unaudited financial results for the three months and six months ended June 30, 2026 ("26Q2" and "26H1", respectively).

26H1 Selected Financial Information

Item


For the six months ended June 30,


Year-over-
year
("YoY")
change


2025


2026



(Unaudited)


(Unaudited)



RMB million


RMB million


US$ million


Revenue


9,393.1


11,498.9


1,694.7


22.4 %

Gross profit


4,156.9


5,093.7


750.7


22.5 %

Operating profit


1,545.9


1,639.9


241.7


6.1 %

Adjusted operating profit(2)
excluding FX(3)


1,550.8


1,628.6


240.0


5.0 %

Profit for the period


906.0


956.6


141.0


5.6 %

Earnings per American
Depositary Share ("ADS")









-Basic earnings per ADS
(RMB and US$)


2.96


3.16


0.47


6.8 %

-Diluted earnings per
ADS (RMB and US$)


2.92


3.16


0.47


8.2 %

Adjusted net profit(2)
excluding FX(3)


1,242.9


1,221.6


180.0


(1.7 %)

Adjusted EBITDA(2)


2,187.6


2,255.5


332.4


3.1 %

Net cash from operating
activities


1,014.2


1,475.4


217.4


45.5 %

Store Network Expansion

As of June 30, 2026, the Company's total store count reached 8,674, representing a net increase of 769 YoY and 189 YTD(4).

  • MINISO Brand: totaled 8,309 stores (up 697 YoY and 158 YTD(4)), driven by:
    • Chinese Mainland: 4,665 stores (up 360 YoY and 97 YTD(4)).
    • Overseas Markets: 3,644 stores (up 337 YoY and 61 YTD(4)).
  • TOP TOY Brand: totaled 365 stores (up 72 YoY and 31 YTD(4)).

The following table provides a breakdown of the Company's store network and its changes on a YoY and YTD(4) basis. About 48.4% of new MINISO stores in the past twelve months were located in overseas markets.


As of




June 30,

2025

December 31,
2025

June 30,

2026

YoY

YTD(4)

Number of stores on group level

7,905

8,485

8,674

769

189

Number of MINISO stores

7,612

8,151

8,309

697

158

Chinese mainland

4,305

4,568

4,665

360

97

— Directly operated stores

20

18

15

(5)

(3)

— Stores operated under Retail
     Partner model

4,258

4,522

4,624

366

102

— Stores operated under
     distributor model

27

28

26

(1)

(2)

Overseas markets

3,307

3,583

3,644

337

61

— Directly operated stores

579

700

795

216

95

— Stores operated under Retail
     Partner model

425

432

439

14

7

— Stores operated under
     distributor model

2,303

2,451

2,410

107

(41)







Number of TOP TOY stores

293

334

365

72

31

Chinese mainland

283

304

317

34

13

— Directly operated stores

33

35

33

-

(2)

— Stores operated under Retail
     Partner model

250

269

284

34

15

Overseas markets

10

30

48

38

18

— Directly operated stores

5

15

30

25

15

— Stores operated under Retail
     Partner model

-

4

4

4

-

— Stores operated under
     distributor model

5

11

14

9

3

Mr. Guofu Ye, Founder, Chairman and CEO of MINISO, commented, "Despite a challenging consumer environment in the domestic market during 26H1, we are pleased to see that MINISO Chinese mainland delivered a standout performance, with revenue growing 26.2% YoY, our fastest first-half growth rate in the past three years, driven by mid-single-digit SSSG. MINISO overseas markets grew 14.9% YoY, while TOP TOY grew 32.7% YoY."

"Beyond the financial performance, we would also like to share our progress on proprietary IP and membership operations. YOYO, launched just one year ago, achieved monthly sales exceeding RMB100 million in both June and July 2026 and completed its first crossover collaboration with a world-class IP, evolving into an IP asset capable of engaging and co-creating with international IPs on equal footing. Members of MINISO Chinese mainland grew 31.0% YoY to about 130 million, contributing 77.4% of local sales; in the United States, our members grew 107.1% YoY to about 5.8 million, contributing 60.1% of local sales. Our membership program highlighted strong user retention, cementing the foundation for sustainable commercialization and long-term brand equity. On the global front, we celebrated our market entry into Switzerland in 26Q2, extending our global footprint to accumulative 113 countries and regions, while TOP TOY officially entered the United States and Taiwan, China, further elevating its global presence."

"Moving forward, MINISO will keep focusing on its dual drivers: IP and large-format stores. We aim to unlock deep brand equity via our IP ecosystem and reshape retail experiences through large-format stores. Guided by long-termism, we balance global expansion with high-quality localization. Powered by operational resilience, MINISO will create enduring, cycle-defying value for global stakeholders." Mr. Ye continued.

Mr. Eason Zhang, CFO of MINISO, commented, "During 26H1, revenue on group level grew by 22.4%. Adjusted operating profit excluding FX grew 5.0% YoY to RMB1,628.6 million. Net cash generated from operating activities reached RMB1,475.4 million, while adjusted net profit excluding FX was RMB1,221.6 million in the same period, demonstrating strong resilience and robust operational cash flow generation of our business."

"Our capital allocation initiatives were highlighted by share repurchase of RMB517.6 million deployed by the Company in 26H1, accounting for more than 90% of full-year repurchase amount of 2025. Furthermore, in June 2026, the Board approved 2026 share repurchase program of up to HK$2.0 billion, alongside an automatic share repurchase plan, enabling continued buyback execution even during blackout periods across both Hong Kong and the U.S. markets, underscoring our disciplined capital deployment, and reaffirmed our unwavering confidence in MINISO Group's intrinsic value.

We have returned a total of RMB1.31 billion to shareholders by cash dividends and share repurchases, accounting for 121% of the adjusted net profit for 26H1, which far exceeded the 50% payout ratio per our current dividend policy. Looking ahead, our capital allocation strategy will continue to balance our high-growth trajectory with our commitment to delivering stable, predictable returns to our shareholders." Mr. Zhang concluded.

Financial Results for 26H1

Revenue was RMB11,498.9 million (US$1,694.7 million), representing an increase of 22.4% YoY.

Revenue from MINISO brand increased by 21.6% YoY to RMB10,513.2 million (US$1,549.5 million), mainly driven by (i) an increase of 26.2% in revenue from Chinese mainland, powered by its mid-single digit SSSG(1), and (ii) an increase of 14.9% in revenue from overseas markets, with low-single-digit decline in same-store GMV. Overseas markets revenue contributed 38.6% of revenue from MINISO brand, compared to 40.9% in the same period last year.

Revenue from TOP TOY brand(5) increased by 32.7% YoY to RMB984.6 million (US$145.1 million).

For more information on the composition and YoY change of revenue, please refer to the "Unaudited Additional Information" in this press release.

Cost of sales was RMB6,405.2 million (US$944.0 million), representing an increase of 22.3% YoY.

Gross profit was RMB5,093.7 million (US$750.7 million), representing an increase of 22.5% YoY.

Gross margin was 44.3%, flat year over year. The current-period margin included a benefit of about 0.6% from tariff refunds. The Company estimated more benefit in the coming quarters of about US$4.1 million.

Selling and distribution ("S&D") expenses were RMB3,045.0 million (US$448.8 million), representing an increase of 39.6% YoY. Excluding share-based compensation ("SBC") expenses, S&D expenses were RMB2,961.5 million (US$436.5 million), representing an increase of 36.7% YoY.

As a percentage of revenue, S&D expenses excluding SBC stood at 25.8% in 26H1, compared with 23.1% in the same period last year. This 2.7‑percentage‑point YoY increase was the main driver for the corresponding YoY decline in adjusted net profit margin excluding FX(3).

The YoY expenses increase as percentages of revenue were broken down as follows: a 1.0‑percentage‑point rise in depreciation and amortization and rental expenses for directly‑operated stores; a 0.5‑percentage‑point uptick in promotion and advertising expenses; a 0.5‑percentage‑point increase in licensing expenses, reflecting the Company's strategic investments in IP development to build foundations for future growth; and an approximate 0.4‑percentage‑point increase in payroll expenses excluding SBC, largely attributable to overseas operations. Logistics expenses as a percentage of revenue remained stable at around 1.7%, flat YoY.

General and administrative expenses were RMB590.9 million (US$87.1 million), representing an increase of 17.3% YoY. Excluding SBC expenses, general and administrative expenses were RMB550.8 million (US$81.2 million), representing an increase of 15.5% YoY. The YoY increase was primarily due to the increase in personnel-related expenses in relation to the growth of the Company's business.

Other net income was RMB196.7 million (US$29.0 million), compared to RMB98.2 million in the same period last year. The YoY increase was mainly due to an unrealized mark-to-market gain of RMB277.4 million (US$40.9 million) arising from fair value changes of an investment in a limited partnership, reflecting its early stage strategic pre-IPO investment in the AI industry. This was partially offset by a net foreign exchange loss of RMB142.4 million (US$21.0 million), compared to a net foreign exchange gain of RMB36.6 million in the same period last year.

Operating profit increased by 6.1% YoY to RMB1,639.9 million (US$241.7 million), compared with RMB1,545.9 million in the same period last year.

Operating margin was 14.3%, compared with 16.5% in the same period last year.

Adjusted operating profit(2) was RMB1,486.2 million (US$219.0 million), compared with RMB1,587.4 million in the same period last year. If excluding FX(3), it would have been RMB1,628.6 million (US$240.0 million), representing an increase of 5.0% YoY.

Adjusted operating margin(2) was 12.9%, compared with 16.9% in the same period last year. If excluding FX(3), it would have been 14.2%.

Net finance costs were RMB212.0 million (US$31.2 million), compared to RMB128.4 million in the same period last year. The YoY change was mainly attributable to the decrease in interest income as a result of decreased principal in bank deposit, and increased finance costs. The increase in finance costs was mainly due to (i) increased interest expenses on lease liabilities in line with the Company's investment in directly operated stores; (ii) increased interest expenses in relation to the equity linked securities issued by the Company in 2025 (the "Equity Linked Securities"), and (iii) increased interest expenses mainly attributable to a borrowing in connection with the acquisition of the equity interest in Yonghui Superstores Co., Ltd * (永輝超市股份有限公司) ("Yonghui"). Both (ii) and (iii) are excluded in non-IFRS financial measures(2) and the increases were driven by the full-period recognition of interest in 26H1 versus a pro-rated portion in the prior-year period.

Share of profit of equity-accounted investees, net of tax was RMB57.8 million (US$8.5 million), compared to a share of loss of RMB138.9 million in the same period last year. The YoY improvement was primarily attributable to the Company's share of profit in Yonghui of RMB60.3 million (US$8.9 million), compared to a share of loss in the prior-year period. This reflected Yonghui's return to profitability in 26H1, driven by its ongoing store-remodeling program, strengthened private-label merchandise portfolio, and improved gross margin and operating expense discipline, as disclosed in Yonghui's 2026 interim report. The share of profit in Yonghui has been excluded in the Company's non-IFRS financial measures(2), as it relates to the operating results of an associated company rather than the underlying performance of MINISO's own business.

Changes in fair value of redemption liabilities were RMB47.4 million (US$7.0 million), which was a non-cash loss arising from preferred shares issued by TOP TOY in connection with its strategic financing in 2025 and has been excluded in non-IFRS financial measures(2).

Other expenses were RMB141.3 million (US$20.8 million), representing a non-cash loss from fair value change of certain derivative under mark-to-market impact, which was in relation to the Equity Linked Securities and has been excluded in non-IFRS financial measures(2).

Effective tax rate was 26.2%, compared to 24.1% in the same period last year.

Adjusted effective tax rate(2) was 24.8%, which excluded the impact on effective tax rate as a result of adjusted items, compared to 18.4% in the same period last year. The YoY increase mainly reflected the tax effect of net foreign exchange loss and loss from certain subsidiaries of the Company.

Profit for the period increased 5.6% YoY to RMB956.6 million (US$141.0 million), compared to RMB906.0 million in the same period last year. The YoY increase was primarily attributable to the following factors: (i) the unrealized mark-to-market gain of RMB277.4 million (US$40.9 million) from fair value changes of an investment in a limited partnership investing in the AI industry, and (ii) RMB60.3 million (US$8.9 million) share of profit from its investment in Yonghui. Such positive contributions were partially offset by the following factors: (i) higher S&D expenses compared with the prior-year period, (ii) net foreign exchange loss of RMB142.4 million (US$21.0 million), reversing the net foreign exchange gain of RMB36.6 million recorded in the same period last year, (iii) increased net finance costs explained above, and (iv) a loss arising from changes in fair value of redemption liabilities arising from preferred shares issued by TOP TOY in connection with its strategic financing in 2025.

Net profit margin was 8.3%, compared to 9.6% in the same period last year.

Adjusted net profit(2) was RMB1,079.1 million (US$159.0 million), compared to RMB1,279.5 million in the same period last year. If excluding FX(3), it would have been RMB1,221.6 million (US$180.0 million), compared to RMB1,242.9 million in the same period last year.

Adjusted net margin(2) was 9.4%, compared to 13.6% in the same period  last year. If excluding FX(3), it would have been 10.6%, compared to 13.2% in the same period last year.

Adjusted EBITDA(2) increased by 3.1% YoY to RMB2,255.5 million (US$332.4 million).

Adjusted EBITDA margin(2) was 19.6%, compared to 23.3% in the same period last year.

Basic earnings per ADS was RMB3.16 (US$0.47), compared to RMB2.96 in the same period last year, representing an increase of 6.8% YoY.

Diluted earnings per ADS was RMB3.16 (US$0.47), compared to RMB2.92 in the same period last year, representing an increase of 8.2% YoY.

Adjusted basic and diluted earnings per ADS(2) were both RMB3.56 (US$0.52), compared to both RMB4.16 in the same period last year.

Cash position(6), which was the combined balance of the Company's cash and cash equivalents, restricted cash, term deposits and other investments recorded as current assets, was RMB7,394.2 million (US$1,089.8 million) as of June 30, 2026, compared to RMB7,087.9 million as of December 31, 2025.

Net cash from operating activities was RMB1,475.4 million (US$217.4 million) for 26H1, with a cash conversion ratio(7) of 1.4. Capital expenditure was RMB724.6 million (US$106.8 million) and free cash flow was RMB750.8 million (US$110.6 million).

Financial Results for 26Q2

Revenue was RMB5,810.5 million (US$856.4 million), representing an increase of 17.0% YoY.

Revenue from MINISO brand increased by 17.0% to RMB5,339.8 million (US$787.0 million), driven by (i) an increase of 22.9% in Chinese mainland, and (ii) an increase of 9.1% in overseas markets.

Revenue from TOP TOY brand(5) increased by 16.9% to RMB470.1 million (US$69.3 million).

For more information on the composition and YoY change of revenue, please refer to the "Unaudited Additional Information" in this press release.

Cost of sales was RMB3,180.9 million (US$468.8 million), representing an increase of 14.9% YoY.

Gross profit was RMB2,629.6 million (US$387.6 million), representing an increase of 19.6% YoY.

Gross margin was 45.3%, compared to 44.3% in the same period last year. The current-period margin included a benefit of about 1.2% from tariff refunds in 26Q2.

S&D expenses were RMB1,574.1 million (US$232.0 million), representing an increase of 35.7% YoY. Excluding SBC expenses, S&D expenses were RMB1,566.8 million (US$230.9 million), representing an increase of 35.7% YoY.

As a percentage of revenue, S&D expenses excluding SBC stood at 27.0% in 26Q2, compared with 23.2% in the same period last year. This 3.8-percentage-point YoY increase was the main driver for the corresponding YoY decline in adjusted net profit margin excluding FX(3).

General and administrative expenses were RMB293.7 million (US$43.3 million), representing an increase of 12.3% YoY. Excluding SBC expenses, general and administrative expenses were RMB286.0 million (US$42.2 million), representing an increase of 13.7% YoY.

Other net loss was RMB625.2 million (US$92.1 million), compared to an income of RMB77.4 million in the same period last year. The YoY change was mainly due to (i) an unrealized mark-to-market loss of RMB597.2 million (US$88.0 million) arising from fair value changes of an investment in a limited partnership, reflecting its early stage strategic pre-IPO investment in the AI industry, and (ii) a net foreign exchange loss of RMB59.9 million (US$8.8 million), compared with a net exchange gain of RMB35.0 million in the same period last year.

Operating profit was RMB118.5 million (US$17.5 million), compared with RMB836.2 million in the same period last year. The decrease in operating profit was mainly due to (i) an unrealized mark-to-market loss of RMB597.2 million (US$88.0 million) from fair value changes of an investment in a limited partnership investing in the AI industry, (ii) increased S&D expenses, and (iii) net foreign exchange loss of RMB59.9 million (US$8.8 million), compared to the net foreign exchange gain of RMB35.0 million in the same period last year.

Operating margin was 2.0%, compared with 16.8% in the same period last year.

Adjusted operating profit(2) was RMB730.7 million (US$107.7 million), compared with RMB852.6 million in the same period last year. If excluding FX, it would have been RMB790.6 million (US$116.5 million), representing a decrease of 3.3% YoY.

Adjusted operating margin(2) was 12.6%, compared with 17.2% in the same period last year. If excluding FX, it would have been 13.6%, compared to 16.5% in the same period last year.

Net finance costs were RMB108.0 million (US$15.9 million), compared to RMB79.4 million in the same period last year.

Share of loss of equity-accounted investees, net of tax was RMB20.4 million (US$3.0 million), compared to RMB136.9 million in the same period last year.

Changes in fair value of redemption liabilities were RMB25.9 million (US$3.8 million), which was a non-cash loss arising from preferred shares issued by TOP TOY in connection with its strategic financing in 2025 and has been excluded in non-IFRS financial measures(2).

Other expenses were RMB90.5 million (US$13.3 million), including a non-cash loss from fair value changes of certain derivative under mark-to-market impact, which was in relation to the Equity Linked Securities and has been excluded in non-IFRS financial measures(2).

Effective tax rate was negative 130.8%, compared to 21.9% in the same period last year. The negative effective tax rate for 26Q2 was driven by the consolidated pre-tax loss, which was primarily impacted by share of loss in Yonghui and an unrealized mark-to-market loss from fair value changes of an investment in a limited partnership investing in the AI industry, while income tax expense was recognized on profitable taxable entities within MINISO Group.

Adjusted effective tax rate(2) was 24.7%, which excluded the impact on effective tax rate as a result of adjusted items, compared to 16.5% in the same period last year. The YoY increase mainly reflected the tax effect of net foreign exchange loss and loss from certain subsidiaries of the Company.

Loss for the period was RMB291.5 million (US$43.0 million), compared to a profit for the period of RMB489.5 million in the same period last year. The loss for the period was mainly attributable to (i) the change in operating profit explained above, and (ii) other expenses of RMB90.5 million (US$13.3 million), compared to other gain of RMB6.7 million in the same period last year, partially offset by the decrease in share of loss in Yonghui.

Net loss margin was 5.0%, compared with a net profit margin of 9.9% in the same period last year.

Adjusted net profit(2) was RMB528.6 million (US$77.9 million), compared to RMB692.3 million in the same period last year. If excluding FX(3), it would have been RMB588.4 million (US$86.7 million), compared to RMB657.3 million in the same period last year.

Adjusted net margin(2) was 9.1%, compared to 13.9% in the same period last year. If excluding FX(3), it would have been 10.1%, compared to 13.2% in the same period last year.

Adjusted EBITDA(2) was RMB1,149.8 million (US$169.5 million), flat YoY.

Adjusted EBITDA margin(2) was 19.8%, compared to 23.2% in the same period last year.

Basic and diluted loss per ADS were both RMB0.96 (US$0.14), compared to both basic and diluted earnings per ADS of RMB1.60 in the same period last year.

Adjusted basic and diluted earnings per ADS(2) were both RMB1.76 (US$0.26), compared to RMB2.24 in the same period last year.

Net cash from operating activities was RMB1,110.2 million (US$163.6 million) for 26Q2, with a cash conversion ratio(7) of 2.1. Capital expenditure was RMB454.0 million (US$66.9 million) and free cash flow was RMB656.2 million (US$96.7 million).

Notes:

  1. "SSSG" refers to the YoY growth of same-store GMV. For overseas markets, to exclude impact from foreign currency fluctuation, such growth is calculated by translating current period same-store GMV in foreign currencies using the prior year's monthly average exchange rates. Same-store GMV represents GMV generated by those MINISO stores that had been open for at least 15 months prior to the beginning of the relevant comparative period and were in normal operating status as of the end of each such period.
  2. See the sections titled "Non-IFRS Financial Measures" and "Reconciliation of Non-IFRS Financial Measures" in this press release for more information.
  3. "FX" refers to net foreign exchange gain or loss for the periods.
  4. "YTD" refers to the six months ended June 30, 2026.
  5. Revenue from TOP TOY brand only represents revenue generated from external parties
  6. "Cash position" refers to the combined balance of the Company's cash and cash equivalents, restricted cash, term deposits with original maturity over three months, and other investments recorded as current assets.
  7. "Cash conversion ratio" refers to the ratio of net cash from operating activities divided by adjusted net profit for the period.

Conference Call

The Company's management will hold an earnings conference call at 5:00 A.M. Eastern Time on Friday, August 28, 2026 (5:00 P.M. Beijing Time on the same day) to discuss the financial results. Simultaneous interpretation in English will be provided during the conference call. The conference call can be accessed by the following Zoom link or dialing the following numbers:

Access 1

Join Zoom meeting.

Zoom link: https://zoom.us/j/92213968231?pwd=6BiFT3ctp5uUiNjunNOPuKtKIadH7g.1
Meeting Number: 922 1396 8231
Meeting Passcode: 9896

Access 2

Listeners may access the call by dialing the following numbers and using the same meeting number and passcode as access 1.

United States:

+1 689 278 1000 (or +1 719 359 4580)

Hong Kong, China:

+852 5803 3730 (or +852 5803 3731)

United Kingdom:

+44 203 481 5237 (or +44 131 460 1196)

France:

+33 1 7037 9729 (or +33 1 7037 2246)

Singapore:

+65 3158 7288 (or +65 3165 1065)

Canada:

+1 438 809 7799 (or +1 204 272 7920)

Access 3

Listeners can also access the meeting through the Company's investor relations website at https://ir.miniso.com/.

The replay will be available approximately two hours after the conclusion of the live event at the Company's investor relations website at https://ir.miniso.com/.

About MINISO Group

MINISO Group is a global high-growth value retailer offering a variety of trendy lifestyle products featuring distinctive IP designs. Since opening our first store in Chinese mainland in 2013, the Company has successfully built two brands – "MINISO" and "TOP TOY". The Company's flagship brand "MINISO" has grown into a globally recognized retail brand that offers a frequently-refreshed assortment of lifestyle products through an extensive store network worldwide. The Company's products cover diverse consumer needs and consumers are drawn to MINISO for our products' trendiness, creativeness, high quality and affordability. For more information, please visit https://ir.miniso.com/.

Exchange Rate

The U.S. dollar (US$) amounts disclosed in this press release, except for those transaction amounts that were actually settled in U.S. dollars, are presented solely for the convenience of the readers. The conversion of Renminbi (RMB) into US$ in this press release is based on the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of June 30, 2026, which was RMB6.7851 to US$1.0000. The percentages stated in this press release are calculated based on the RMB amounts.

Non-IFRS Financial Measures 

In evaluating the business, MINISO considers and uses adjusted operating profit, adjusted operating margin, adjusted effective tax rate, adjusted net profit, adjusted net margin, adjusted EBITDA, adjusted EBITDA margin, adjusted basic and diluted net earnings per share and adjusted basic and diluted net earnings per ADS as supplemental measures to review and assess its core business performance. The presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. MINISO defines adjusted operating profit as operating profit for the period excluding (i) equity-settled share-based payment expenses and (ii) gain or loss from fair value changes of an investment in a limited partnership investing in the AI industry. MINISO calculates adjusted operating margin by dividing adjusted operating profit by revenue for the same period. MINISO defines adjusted effective tax rate as the effective tax rate excluding the tax impact of adjusted items, under non-IFRS financial measures. MINISO defines adjusted net profit as profit for the period excluding (i) equity-settled share-based payment expenses, (ii) gain or loss from fair value change of derivatives, (iii) issuance cost of derivatives, (iv) interest expenses related to the Equity Linked Securities and interest expenses related to the bank loans used for acquisition of the equity interest in Yonghui, (v) share of profit or loss of Yonghui, net of tax, (vi) changes in fair value of redemption liabilities arising from preferred shares, and (vii) gain or loss from fair value changes of an investment in a limited partnership investing in the AI industry. MINISO calculates adjusted net margin by dividing adjusted net profit by revenue for the same period. MINISO defines adjusted EBITDA as adjusted net profit plus (i) depreciation and amortization, (ii) finance costs excluding interest expenses related to the Equity Linked Securities and interest expenses related to the bank loans used for acquisition of the equity interest in Yonghui, and (iii) income tax expense. Adjusted EBITDA margin is computed by dividing adjusted EBITDA by revenue for the period. MINISO computes adjusted basic and diluted net earnings per ADS by dividing adjusted net profit attributable to the equity shareholders of the Company by the number of ADSs represented by the number of ordinary shares used in the basic and diluted earnings per share calculation on an IFRS basis. MINISO computes adjusted basic and diluted net earnings per share in the same way as it calculates adjusted basic and diluted net earnings per ADS, except that it uses the number of ordinary shares used in the basic and diluted earnings per share calculation on an IFRS basis as the denominator instead of the number of ADSs represented by these ordinary shares. Starting from March quarter 2026, to more accurately reflect the Company's core business performance, the Company has adopted revised definitions of adjusted operating profit and adjusted net profit by excluding gain or loss from fair value changes of an investment in a limited partnership investing in the AI industry from the calculation of these items. The Company recorded loss of nil and RMB829.0 thousand, and gain of RMB25.4 million and RMB53.8 million from fair value changes of an investment in a limited partnership investing in the AI industry for the three months ended March 31, June 30, September 30, and December 31, 2025, respectively. To ensure comparability, the Company has retrospectively adjusted its non-IFRS financial measures for prior periods.

MINISO presents these non-IFRS financial measures because they are used by the management to evaluate its core business performance and formulate business plans. These non-IFRS financial measures enable the management to assess its core business results without considering the impacts of the aforementioned non-cash and other adjustment items that MINISO does not consider to be indicative of its core business performance in the future. Accordingly, MINISO believes that the use of these non-IFRS financial measures provides useful information to investors and others in understanding and evaluating its core business results in the same manner as the management and board of directors.

These non-IFRS financial measures are not defined under IFRS and are not presented in accordance with IFRS. These non-IFRS financial measures have limitations as analytical tools. One of the key limitations of using these non-IFRS financial measures is that they do not reflect all items of income and expense that affect MINISO's core business. Further, these non-IFRS financial measures may differ from the non-IFRS information used by other companies, including peer companies, and therefore their comparability may be limited.

These non-IFRS financial measures should not be considered in isolation or construed as alternatives to operating profit, operating margin, effective tax rate, profit, net profit margin, basic and diluted earnings per share and basic and diluted earnings per ADS, as applicable, or any other measures of performance or as indicators of MINISO's core business performance. Investors are encouraged to review MINISO's historical non-IFRS financial measures in light of the most directly comparable IFRS financial measures, as shown below. The non-IFRS financial measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting the usefulness of such measures when analyzing MINISO's data comparatively. MINISO encourages you to review its financial information in its entirety and not rely on a single financial measure.

For more information on the non-IFRS financial measures, please see the table captioned "Reconciliation of Non-IFRS Financial Measures" set forth at the end of this press release.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "anticipate", "aim", "estimate", "intend", "plan", "believe", "is/are likely to", "potential", "continue" or other similar expressions. Among other things, the quotations from management in this announcement, as well as MINISO's strategic and operational plans, contain forward-looking statements. MINISO may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC") and The Stock Exchange of Hong Kong Limited (the "HKEX"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about MINISO's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: MINISO's mission, goals and strategies; future business development, financial conditions and results of operations; the expected growth of the retail market and the market of branded variety retail of lifestyle products in China and globally; expectations regarding demand for and market acceptance of MINISO's products; expectations regarding MINISO's relationships with consumers, suppliers, Retail Partners, local distributors, and other business partners; competition in the industry; proposed use of proceeds; and relevant government policies and regulations relating to MINISO's business and the industry. Further information regarding these and other risks is included in MINISO's filings with the SEC and the HKEX. All information provided in this press release and in the attachments is as of the date of this press release, and MINISO undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Investor Relations Contact:

MINISO Group Holding Limited
Email: [email protected]
Phone: +86 (20) 36228788 Ext.8039

MINISO GROUP HOLDING LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

(Expressed in thousands)




As at


As at



December 31, 2025


June 30, 2026



(Audited)


(Unaudited)



RMB'000


RMB'000


US$'000

ASSETS







Non-current assets







Property, plant and equipment


2,109,385


2,583,756


380,799

Right-of-use assets


5,121,039


5,959,936


878,386

Intangible assets


94,951


225,543


33,241

Goodwill


223,187


210,946


31,090

Deferred tax assets


288,679


320,700


47,265

Other investments


201,727


479,160


70,619

Trade and other receivables


247,511


292,140


43,056

Financial derivative assets


774,103


321,925


47,446

Interests in equity-accounted
investees


5,486,648


5,555,912


818,840










14,547,230


15,950,018


2,350,742








Current assets







Other investments


-


100,351


14,790

Inventories


3,691,238


3,544,387


522,378

Trade and other receivables


3,307,129


3,453,949


509,050

Cash and cash equivalents


6,817,129


7,046,857


1,038,578

Restricted cash


54,229


5,931


874

Term deposits


216,567


241,074


35,530










14,086,292


14,392,549


2,121,200








Total assets


28,633,522


30,342,567


4,471,942

 

MINISO GROUP HOLDING LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (CONTINUED)

(Expressed in thousands)




As at


As at



December 31, 2025


June 30, 2026



(Audited)


(Unaudited)



RMB'000


RMB'000


US$'000

EQUITY







Share capital


94


94


14

Additional paid-in capital


2,887,905


2,080,167


306,579

Other reserves


2,232,854


1,771,661


261,111

Retained earnings


5,497,910


6,459,461


952,007








Equity attributable to equity
shareholders of the Company


10,618,763


10,311,383


1,519,711

Non-controlling interests


100,508


110,067


16,222








Total equity


10,719,271


10,421,450


1,535,933








LIABILITIES







Non-current liabilities







Contract liabilities


22,418


24,362


3,591

Loans and borrowings


5,415,416


6,287,885


926,720

Other payables


72,586


79,802


11,761

Lease liabilities


2,713,798


3,463,573


510,467

Financial derivative liabilities


1,184,050


858,687


126,555

Deferred income


33,053


32,570


4,800










9,441,321


10,746,879


1,583,894








Current liabilities







Contract liabilities


388,746


427,640


63,026

Loans and borrowings


1,751,018


2,352,982


346,787

Trade and other payables


4,516,491


4,428,106


652,622

Lease liabilities


950,784


1,114,196


164,212

Deferred income


965


965


142

Current taxation


291,245


247,692


36,505

Redemption liabilities arising
from preferred shares


573,681


602,657


88,821










8,472,930


9,174,238


1,352,115








Total liabilities


17,914,251


19,921,117


2,936,009








Total equity and liabilities


28,633,522


30,342,567


4,471,942

 

MINISO GROUP HOLDING LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

AND OTHER COMPREHENSIVE INCOME

(Expressed in thousands, except for per ordinary share and per ADS data)













Three months ended June 30,


Six months ended June 30,




2025


2026


2025


2026


(Unaudited)

(Unaudited)


(Unaudited)


(Unaudited)




RMB'000


RMB'000


US$'000


RMB'000


RMB'000


US$'000


Revenue


4,966,068


5,810,513


856,364


9,393,112


11,498,901


1,694,728


Cost of sales


(2,767,187)


(3,180,868)


(468,802)


(5,236,194)


(6,405,225)


(944,013)
















Gross profit


2,198,881


2,629,645


387,562


4,156,918


5,093,676


750,715


Other income


2,350


763


112


5,370


6,679


984


Selling and distribution expenses


(1,159,836)


(1,574,119)


(231,996)


(2,181,022)


(3,045,031)


(448,782)


General and administrative
expenses


(261,512)


(293,650)


(43,279)


(503,656)


(590,943)


(87,094)


Other net income/(loss)


77,404


(625,184)


(92,141)


98,239


196,657


28,984


Credit loss on trade and other
receivables


(4,675)


(12,489)


(1,841)


(13,450)


(14,663)


(2,161)


Impairment loss on non-current
assets


(16,450)


(6,465)


(953)


(16,450)


(6,465)


(953)
















Operating profit


836,162


118,501


17,464


1,545,949


1,639,910


241,693


Finance income


28,921


16,275


2,399


65,836


32,749


4,827


Finance costs


(108,291)


(124,226)


(18,309)


(194,236)


(244,722)


(36,068)
















Net finance costs


(79,370)


(107,951)


(15,910)


(128,400)


(211,973)


(31,241)


Share of (loss)/profit of equity-
accounted investees, net of tax


(136,941)


(20,435)


(3,012)


(138,946)


57,757


8,512


Other gain/(expenses)


6,659


(90,498)


(13,338)


(84,412)


(141,336)


(20,830)


Changes in fair value of
redemption liabilities


-


(25,930)


(3,822)


-


(47,368)


(6,981)
















Profit/(loss) before taxation


626,510


(126,313)


(18,618)


1,194,191


1,296,990


191,153


Income tax expense


(136,979)


(165,198)


(24,347)


(288,201)


(340,399)


(50,169)
















Profit/(loss) for the period


489,531


(291,511)


(42,965)


905,990


956,591


140,984
















Attributable to:














Equity shareholders of the
Company


489,688


(289,186)


(42,622)


906,030


961,551


141,715


Non-controlling interests


(157)


(2,325)


(343)


(40)


(4,960)


(731)
















Earnings/(loss) per share for
ordinary shares














-Basic


0.40


(0.24)


(0.04)


0.74


0.79


0.12


-Diluted


0.40


(0.24)


(0.04)


0.73


0.79


0.12
















Earnings/(loss) per ADS














(Each ADS represents 4
ordinary shares)








-Basic


1.60


(0.96)


(0.14)


2.96


3.16


0.47


-Diluted


1.60


(0.96)


(0.14)


2.92


3.16


0.47


 

MINISO GROUP HOLDING LIMITED

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS

AND OTHER COMPREHENSIVE INCOME (CONTINUED)

(Expressed in thousands)

















Three months ended June 30,


Six months ended June 30,




2025


2026


2025


2026


(Unaudited)

(Unaudited)


(Unaudited)


(Unaudited)




RMB'000


RMB'000


US$'000


RMB'000


RMB'000


US$'000
















Profit/(loss) for the period


489,531


(291,511)


(42,965)


905,990


956,591


140,984
















Items that may be reclassified
subsequently to profit or loss:














Exchange differences on
translation of financial statements
of foreign operations


12,966


(27,735)


(4,088)


11,675


(77,115)


(11,365)


Share of other comprehensive
income of equity-accounted
investees


-


1,907


281


-


2,720


401
















Other comprehensive
income/(loss) for the period


12,966


(25,828)


(3,807)


11,675


(74,395)


(10,964)
















Total comprehensive
income/(loss) for the period


502,497


(317,339)


(46,772)


917,665


882,196


130,020
















Attributable to:














Equity shareholders of the
Company


501,095


(309,689)


(45,645)


917,401


894,228


131,793


Non-controlling interests


1,402


(7,650)


(1,127)


264


(12,032)


(1,773)


 

MINISO GROUP HOLDING LIMITED

RECONCILIATION OF NON-IFRS FINANCIAL MEASURES

(Expressed in thousands, except for percentages)

















Three months ended June 30,


Six months ended June 30,




2025


2026


2025


2026




(Unaudited)


(Unaudited)


(Unaudited)


(Unaudited)




RMB'000


RMB'000


US$'000

RMB'000


RMB'000


US$'000
















Reconciliation of operating profit
for the period to adjusted
operating profit














Operating profit


836,162


118,501


17,464


1,545,949


1,639,910


241,693


Add back:














Equity-settled share-based
payment expenses


15,656


15,008


2,212


40,586


123,723


18,235


Loss/(gain) from fair value
changes of an investment in a
limited partnership investing in
the AI industry


829


597,159


88,010


829


(277,434)


(40,889)
















Adjusted operating profit


852,647


730,668


107,686


1,587,364


1,486,199


219,039


Adjusted operating margin


17.2 %


12.6 %


12.6 %


16.9 %


12.9 %


12.9 %
















Reconciliation of operating profit
for the period to adjusted
operating profit excluding FX(1)














Adjusted operating profit


852,647


730,668


107,686


1,587,364


1,486,199


219,039


Add back:














Net foreign exchange (gain)/loss


(34,993)


59,890


8,827


(36,570)


142,438


20,993
















Adjusted operating profit
excluding FX(1)


817,654


790,558


116,513


1,550,794


1,628,637


240,032


Adjusted operating margin
excluding FX
(1)


16.5 %


13.6 %


13.6 %


16.5 %


14.2 %


14.2 %



Note:

(1) "FX" refers to net foreign exchange gain or loss for the period.

 

MINISO GROUP HOLDING LIMITED

RECONCILIATION OF NON-IFRS FINANCIAL MEASURES (CONTINUED)

(Expressed in percentages)













Three months ended June 30,


Six months ended June 30,




2025


2026


2025


2026




(Unaudited)


(Unaudited)


(Unaudited)


(Unaudited)












Reconciliation of effective tax rate to
adjusted effective tax rate:










Effective tax rate


21.9 %


(130.8) %


24.1 %


26.2 %












Impact on effective tax rate as a result
of adjusted items


(5.4) %


155.5 %


(5.7) %


(1.4) %


Adjusted effective tax rate


16.5 %


24.7 %


18.4 %


24.8 %


 

MINISO GROUP HOLDING LIMITED

RECONCILIATION OF NON-IFRS FINANCIAL MEASURES (CONTINUED)

(Expressed in thousands, except for per share, per ADS data and percentages)

















Three months ended June 30,


Six months ended June 30,




2025


2026


2025


2026


(Unaudited)

(Unaudited)


(Unaudited)


(Unaudited)




RMB'000


RMB'000


US$'000


RMB'000


RMB'000


US$'000
















Reconciliation of profit for the
period to adjusted net profit:














Profit/(loss) for the period


489,531


(291,511)


(42,965)


905,990


956,591


140,984


Add back:














Equity-settled share-based
payment expenses


15,656


15,008


2,212


40,586


123,723


18,235


(Gain)/loss from fair value
change of derivatives(1)(2)


(6,659)


90,498


13,338


39,748


141,336


20,830


Issuance cost of derivatives(1)(3)


-


-


-


44,664


-


-


Interest expenses related to the
Equity Linked Securities and the
bank loans used for acquisition of
the equity interest in Yonghui(1)


73,606


74,305


10,951


128,351


147,820


21,786


-Interest expenses related to
the Equity Linked Securities(4)


49,358


51,008


7,518


89,885


101,388


14,943


-Interest expenses related to
the bank loans used for acquisition
of the equity interest in Yonghui


24,248


23,297


3,433


38,466


46,432


6,843


Share of loss/(profit) of Yonghui,
net of tax(1)


119,335


17,169


2,530


119,335


(60,289)


(8,885)


Changes in fair value of redemption
liabilities(1)


-


25,930


3,822


-


47,368


6,981


Loss/(gain) from fair value changes
of an investment in a limited
partnership investing in the AI
industry(5)


829


597,159


88,010


829


(277,434)


(40,889)
















Adjusted net profit


692,298


528,558


77,898


1,279,503


1,079,115


159,042


Adjusted net margin


13.9 %


9.1 %


9.1 %


13.6 %


9.4 %


9.4 %
















Attributable to:














Equity shareholders of the
Company


692,459


530,827


78,232


1,279,458


1,083,167


159,639


Non-controlling interests


(161)


(2,269)


(334)


45


(4,052)


(597)
















Adjusted net earnings per
share
(6)














-Basic


0.56


0.44


0.06


1.04


0.89


0.13


-Diluted


0.56


0.44


0.06


1.04


0.89


0.13
















Adjusted net earnings per
ADS (Each ADS represents 4
ordinary shares)














-Basic


2.24


1.76


0.26


4.16


3.56


0.52


-Diluted


2.24


1.76


0.26


4.16


3.56


0.52


 

MINISO GROUP HOLDING LIMITED

RECONCILIATION OF NON-IFRS FINANCIAL MEASURES (CONTINUED)

(Expressed in thousands, except for percentages)



Three months ended June 30,


Six months ended June 30,




2025


2026


2025


2026




(Unaudited)


(Unaudited)


(Unaudited)


(Unaudited)




RMB'000


RMB'000


US$'000


RMB'000


RMB'000


US$'000
















Reconciliation of adjusted net
profit for the period to adjusted
net profit excluding FX(7):














Adjusted net profit


692,298


528,558


77,898


1,279,503


1,079,115


159,042


Add back:














Net foreign exchange
(gain)/loss


(34,993)


59,890


8,827


(36,570)


142,438


20,993
















Adjusted net profit excluding
FX(7)


657,305


588,448


86,725


1,242,933


1,221,553


180,035


Adjusted net margin
excluding FX(7)


13.2 %


10.1 %


10.1 %


13.2 %


10.6 %


10.6 %
















Reconciliation of adjusted net
profit for the period to adjusted
EBITDA:














Adjusted net profit


692,298


528,558


77,898


1,279,503


1,079,115


159,042


Add back:














Depreciation and amortization


286,344


406,123


59,855


554,016


739,113


108,932


Finance costs excluding
interest expenses related to the
Equity Linked Securities


34,685


49,921


7,358


65,885


96,902


14,282


Income tax expense


136,979


165,198


24,347


288,201


340,399


50,169
















Adjusted EBITDA


1,150,306


1,149,800


169,458


2,187,605


2,255,529


332,425


Adjusted EBITDA margin


23.2 %


19.8 %


19.8 %


23.3 %


19.6 %


19.6 %



Notes:

(1)  These adjustment items have been excluded from the calculation of adjusted net profit as the management of the
Company does not consider such items to be indicative of its performance of core business.

 

(2)  The gain or loss from fair value change of derivatives was a non-cash gain or expense that was related to the fair

value of the Equity Linked Securities and call spread. It was determined primarily by movements in the underlying share

price.

 

(3)  The issuance cost of derivatives was a one-off expense that was related to the Equity Linked Securities.

 

(4)  For 26Q2, the RMB51.0 million interest expenses related to the Equity Linked Securities included RMB46.3 million

non-cash portion and RMB4.7 million cash expense.

 

For 26H1, the RMB101.4 million interest expenses related to the Equity Linked Securities included RMB92.0 million

non-cash portion and RMB9.4 million cash expense.

 

(5)  Gain or loss from fair value changes of an investment in a limited partnership investing in the AI industry was

included in other net income or loss, which was an unrealized gain or loss arising from fair value changes of an investment

in a limited partnership investing in the AI industry.

 

(6)  Adjusted basic and diluted net earnings per share are computed by dividing adjusted net profit attributable to the

equity shareholders of the Company by the number of ordinary shares used in the basic and diluted earnings per share

calculation on an IFRS basis.

 

(7)  "FX" refers to net foreign exchange gain or loss for the period.

 

MINISO GROUP HOLDING LIMITED

UNAUDITED ADDITIONAL INFORMATION

(Expressed in thousands, except for percentages)
















Three months ended June 30,




Six months ended June 30,





2025


2026


YoY


2025


2026


YoY



RMB'000


RMB'000


US$'000




RMB'000


RMB'000


US$'000



Revenue

















MINISO Brand


4,563,226


5,339,823


786,993


17.0 %


8,649,004


10,513,225


1,549,457


21.6 %

-Chinese mainland


2,621,212


3,221,701


474,820


22.9 %


5,114,987


6,453,955


951,195


26.2 %

-Overseas markets


1,942,014


2,118,122


312,173


9.1 %


3,534,017


4,059,270


598,262


14.9 %

TOP TOY Brand(1)


402,208


470,133


69,289


16.9 %


742,058


984,618


145,115


32.7 %

Others


634


557


82


(12.1) %


2,050


1,058


156


(48.4) %



4,966,068


5,810,513


856,364


17.0 %


9,393,112


11,498,901


1,694,728


22.4 %


Note:

 

(1) Revenue from TOP TOY brand only represents revenue generated from external parties.

 

MINISO GROUP HOLDING LIMITED

UNAUDITED ADDITIONAL INFORMATION

NUMBER OF MINISO STORES IN CHINESE MAINLAND








As of







June 30,

2025


December 31,
2025


June 30,

2026


YoY


YTD(1)

By City Tiers










First-tier cities


572


609


611


39


2

Second-tier cities


1,774


1,881


1,928


154


47

Third- and lower-tier cities


1,959


2,078


2,126


167


48

Total


4,305


4,568

4,665


360

97


Note:

 

(1) "YTD" refers to the six months ended June 30, 2026.

 

MINISO GROUP HOLDING LIMITED

UNAUDITED ADDITIONAL INFORMATION

NUMBER OF MINISO STORES IN OVERSEAS MARKETS












As of





By Regions


June 30,
2025


December 31,
2025


June 30,
2026


YoY


YTD(1)










Asia excluding China


1,695


1,793


1,793


98


-

North America


394


461


536


142


75

Latin America


661


722


726


65


4

Europe


319


361


356


37


(5)

Others


238


246


233


(5)


(13)

Total

3,307


3,583


3,644


337

61


Note:

 

(1) "YTD" refers to the six months ended June 30, 2026.

 

*For identification purpose only

 

Information Provided by PR Newswire [Disclaimer]
12:31
HSI Reverts Up 119 Pts at Half-day; TENCENT Up 2%; KB LAMINATES Up 4%+; Lithium Shares Pick Up

This morning (28th), the HSI opened down 155 pts before reversing higher. At midday, the index closed at 25,684, up 119 pts or 0.47%, with market turnover at HKD117.498 billion. The HSCEI finished at 8,534, up 44 pts or 0.52%. The HSTECH hiked 27 pts or 0.6% to settle at 4,648.

Among major techs, TENCENT (00700.HK) reversed losses after opening lower and mounted 2.19%; XIAOMI-W (01810.HK) rallied 2.62%; KUAISHOU-W (01024.HK) climbed 1.37%; MEITUAN-W (03690.HK) and BIDU-SW (09888.HK) added less than 1%. BABA-W (09988.HK) dipped 0.78%.

Among blue chips, OOIL (00316.HK) logged a nearly 24% decline in 1H profit, with shares falling 7.43% by midday, making it the worst-performing blue chip. HSMIC (00981.HK) lifted 0.42% after interim net profit surged 1.1x. CHINA LIFE (02628.HK) grew 1.23% after interim dividend spiked 50%. SUNNY OPTICAL (02382.HK) advanced 4.06% after results and a TP upgrade by Citi. BOC HONG KONG (02388.HK) strengthened ahead of earnings announcement, closing up 2.57% at midday.

KINGBOARD HLDG (00148.HK)'s controlling shareholder increased holdings by 200,000 shares on Wednesday, while KINGBOARD HLDG also increased its stake in KB LAMINATES (01888.HK) by 575,500 shares on the same day. KB LAMINATES soared another 4.23%, while KINGBOARD HLDG (00148.HK) dipped 0.09%.

Lithium stocks picked up. TIANQI LITHIUM (09696.HK) rallied 4.6% after 1H profit swelled nearly 48x; GANFENGLITHIUM (01772.HK) jumped up 2.2%; CATL (03750.HK) inched up 0.73%; and BYD ELECTRONIC (00285.HK) escalated 6.61%, becoming the best-performing blue chip at midday.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
10:50
AWS, NVIDIA Expand Strategic Partnership; AWS to Become Best Venue for Running NVIDIA AI Tech

Amazon.com, Inc. (AMZN.US)'s Amazon Web Services (AWS) and NVIDIA Corporation (NVDA.US) radically expanded their strategic partnership.

The two parties plan to deploy an additional 2 million NVIDIA GPUs across AWS's global infrastructure, while deepening cooperation in AI factories, CPUs, networking, open models, data processing and robotics technologies.

Through jointly designed solutions, they aim to help customers accelerate AI development at unprecedented scale. NVIDIA Vera CPU will be launched on AWS, providing additional computing options for Agentic AI.

The expanded partnership complements AWS's in-house chip product lineup, enabling customers to flexibly choose the optimal computing solution based on specific workloads, whether using NVIDIA GPUs, Amazon Trainium chips, or a combination of both.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
10:44
Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's

HONG KONG, Aug. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue, further advanced its global immuno-oncology (IO) 2.0 strategy, progressively built its IO2.0 + ADC2.0 therapeutic matrix, and continued orderly development of bispecific antibodies in major chronic disease areas, including autoimmune, respiratory, and central nervous system (CNS) disorders

Commercialization Reaches Record High

Commercial sales revenue for the first half of 2026 reached approximately RMB 1,803.2 million, representing a 28.7% increase year-over-year. As of the reporting date, the Company's total cash and cash equivalents, together with other short-term financial assets, stood at RMB 9,160.0 million.

By the end of 2025, all 12 indications across the Company's five self-commercialized innovative drugs had been included in China's National Reimbursement Drug List (NRDL). These include two non-small cell lung cancer (NSCLC) indications for ivonescimab (PD-1/VEGF bispecific antibody) and three cervical and gastric cancer indications for cadonilimab (PD-1/CTLA-4 bispecific antibody). NRDL inclusion has significantly expanded market coverage and patient access.

In August 2026, the National Medical Products Administration (NMPA) approved ivonescimab in combination with chemotherapy for the first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC), providing a new growth driver for commercialization.

Since the beginning of 2026, the Company has continued to strengthen its commercialization capabilities, with steady progress in market access, coverage, and penetration. These efforts lay a solid foundation for the sustained release of innovative drug value in the second half of the year and beyond.

IO2.0 Global Strategy Advances

Following the approvals of ivonescimab and cadonilimab - two first-in-class immuno-oncology (IO) cornerstone therapies - Akeso has continued to advance the Company's global IO2.0+ strategy. The Company is building a bispecific antibody-based IO therapeutic matrix designed to treat multiple tumor types through combining different types of therapy.

Biliary tract cancer: In August 2026, the Phase III clinical study of ivonescimab plus chemotherapy versus durvalumab plus chemotherapy for the first-line treatment of advanced biliary tract cancer met its primary endpoint of overall survival (OS), demonstrating clinically meaningful and statistically significant OS benefit. This regimen represents a major advancement in first-line treatment of biliary tract cancer.

Squamous NSCLC: In August 2026, ivonescimab plus chemotherapy received NMPA approval for first-line treatment of sq-NSCLC. Based on the HARMONi-6 study, this is the first regimen to achieve dual positive OS and progression-free survival (PFS) results versus a PD-1 monoclonal antibody plus chemotherapy in a randomized, double-blind Phase III trial. Ivonescimab combination therapy marks a significant advance in first-line sq-NSCLC treatment.

EGFR-TKI-resistant NSCLC: In July 2026, an updated analysis of the global multicenter Phase III HARMONi study demonstrated continued OS improvement (HR = 0.76). The OS hazard ratio in Western patients was also 0.76, highly consistent with the China-conducted HARMONi-A study (HR = 0.74, P = 0.02). The Biologics License Application (BLA) for this indication is currently under review by the U.S. Food and Drug Administration (FDA). The HARMONi-A study is the first immuno-oncology trial globally to achieve dual positive OS and PFS results with both clinical benefit and statistical significance in this setting. Ivonescimab combination therapy represents a major advancement in the treatment of EGFR-TKI-resistant non-squamous NSCLC.

PD-L1-positive NSCLC: In the HARMONi-2 study, ivonescimab became the first therapy globally to demonstrate positive results versus pembrolizumab in a Phase III trial, establishing a new benchmark in first-line treatment of PD-L1-positive NSCLC.

Cadonilimab: Cadonilimab continues to advance across multiple indications, including gastric cancer and hepatocellular carcinoma (HCC). Key programs include an international multicenter Phase III study of cadonilimab plus chemotherapy versus nivolumab plus chemotherapy for first-line treatment of gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, a perioperative Phase II study in collaboration with Memorial Sloan Kettering Cancer Center (MSKCC), and an international multicenter registrational study of cadonilimab plus lenvatinib in HCC patients who progressed after prior atezolizumab plus bevacizumab.

As cornerstone agents of global IO2.0, ivonescimab and cadonilimab are establishing a combination therapy ecosystem through novel mechanisms, with the potential to elevate the standard of care across multiple tumor types. Ivonescimab is currently being evaluated in combination trials with Revolution Medicines' RAS(ON) inhibitor, ARCUS Biosciences' HIF-2α inhibitor, Virogin Biotech's VG201 oncolytic virus, and TransThera Biosciences' tinengotinib, spanning NSCLC, pancreatic cancer, colorectal cancer, clear cell renal cell carcinoma, and hepatocellular carcinoma. Cadonilimab is advancing multi-pathway combination strategies, including combinations with small molecules such as axitinib and tinengotinib in renal and liver cancers, as well as collaborations with the Dana-Farber Cancer Institute and Mass General Brigham to evaluate cadonilimab in combination with INOVIO's DNA medicine INO-5412 in glioblastoma (GBM).

Ivonescimab is currently being evaluated in more than 17 registrational Phase II/III studies, including seven global registrational trials and 8 studies that use standard-of-care regimens as active comparators. These programs encompass 8 registrational/Phase III studies in lung cancer, as well as first-line MSS/pMMR colorectal cancer, first-line PD-L1-positive head and neck squamous cell carcinoma (in combination with CD47 antibody versus pembrolizumab), first-line biliary tract cancer (versus a durvalumab-based regimen), first-line triple-negative breast cancer, first-line pancreatic cancer, and first-line urothelial cancer (versus pembrolizumab plus a Nectin-4 ADC).

Cadonilimab is being evaluated in more than 13 registrational/Phase III clinical studies covering major cancer types, including gastric cancer, HCC, lung cancer, cervical cancer, pancreatic cancer, and esophageal squamous cell carcinoma. Two of these are international multicenter registrational studies.

IO2.0 + ADC2.0 Therapeutic Matrix

Akeso is the only company globally with two approved immuno-oncology bispecific antibodies and is actively exploring combination therapies of ivonescimab and cadonilimab with both proprietary and partnered antibody-drug conjugates (ADCs).

The Company has developed a series of next-generation ADCs designed to address the narrow therapeutic window associated with the safety limitations of existing ADC therapies. Among these, the innovative TROP2/Nectin-4 bispecific ADC AK146D1, next-generation HER3 ADC AK138D1, next-generation B7H3 ADC AK157D1, and bispecific ADC AK158D1 have successively entered clinical development.

Multiple Phase II studies evaluating AK146D1 in combination with ivonescimab in NSCLC, breast cancer, and urothelial cancer, as well as AK138D1 in combination with ivonescimab in lung and breast cancers, are underway, with a focus on first-line treatment of various solid tumors.

In parallel, ivonescimab has entered combination therapy collaborations with high-potential ADCs from domestic and international partners, including Pfizer, GSK, Biokin, and MediLink. These collaborations cover agents such as EGFR/HER3 bispecific ADC, TROP2/HER3 bispecific ADC, B7H3 ADC, FGFR2b ADC, TROP2 ADC, and Nectin-4 ADC across high-incidence malignancies.

Looking further ahead, the Company's frontier programs continue to push additional new therapies into the clinic. The global first-in-class trispecific antibody AK150 (ILT2/ILT4/CSF1R) has entered clinical development, with additional trispecific antibodies and T-cell engager (TCE) bispecific/multispecific candidates expected to enter the clinic in the next year.

Entering the Bispecific Era in Immunology, CNS, and Respiratory Diseases

In autoimmune, respiratory, and CNS diseases, Akeso is leveraging its expertise in bispecific and multispecific antibody development, with strategic momentum steadily building. A series of internally-developed novel candidates, including AK139, a bispecific antibody for Immunology & Inflammation that targets IL-4R and ST2, and AK152, a bispecific amyloid-beta + brain shuttle antibody for the treatment of Alzheimer's disease have entered or are preparing to enter clinical development. These programs form a complementary pipeline alongside the Company's already marketed non-oncology products: ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), gumokimab (IL-17), and manfidokimab (IL-4Rα).

AI-Empowered Future Innovation Competitiveness

Akeso has adopted the use of AI in its R&D efforts for the past few years. The Company is further expanding the implementation of AI in many new scientific directions and therapeutic platforms.

Developed on Akeso's AI-driven drug discovery platform, AK139, an IL-4Rα/ST2 bispecific antibody, has advanced into 7 Phase II trials across respiratory and autoimmune indications. AK150, an ILT2/ILT4/CSF1R trispecific antibody, is in Phase I development. AK154, a personalized mRNA cancer vaccine that leverages AI-powered selection of high-affinity immunogenic mutations to create precision oncology therapies. A Phase I study of AK154 as monotherapy or in combination with cadonilimab or ivonescimab as adjuvant therapy in pancreatic cancer is currently ongoing.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multispecific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.

Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

Information Provided by PR Newswire [Disclaimer]
09:39
HSI Opens Down 155 pts; BABA-W Slips 2%; SHIMAO GROUP Opens Down 10% on Winding-up Petition

The three major US stock indices closed higher, with the Nasdaq gaining more than 1%, driven by an 8.7% surge in NVIDIA Corporation (NVDA.US) after strong earnings results.

This morning (28th), the HSI opened at 25,410, down 155 points or 0.61%; the HSTECH opened at 4,580, down 39 points or 0.85%; and the HSCEI opened at 8,425, down 64 points or 0.76%.

Among major techs, BABA-W (09988.HK) lost 2.08%; MEITUAN-W (03690.HK), JD-SW (09618.HK) and BIDU-SW (09888.HK) shed more than 1%; while TENCENT (00700.HK) lost 0.85%.

Among blue chips, OOIL (00316.HK) opened 5.5% lower after its 1H profit dropped nearly 24%; HAIER SMARTHOME (06690.HK) slid 3.55% after results; SMIC (00981.HK) rose 0.42% after its interim net profit spiked 1.1x; CHINA LIFE (02628.HK) added 0.82% after interim dividend jumped up 50%; INNOVENT BIO (01801.HK) dived 2.14% after Temasek reduced its stake to below 5%.

Several Chinese banks are set to announce results shortly. ABC (01288.HK) faded 1.36%; BANK OF CHINA (03988.HK) opened 0.45% lower; ICBC (01398.HK) opened down 1.01%; and BANKCOMM (03328.HK) opened down 1.66%.

Among individuals, BILIBILI-W (09626.HK) gained 1.77% after adjusted net profit for the previous quarter climbed 25%; SHIMAO GROUP (00813.HK) faced another winding-up petition, with shares opening 10.45% lower.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
09:28
BABA-W CEO Eddie Wu Named to TIME100 AI 2026 List

TIME magazine released its TIME100 AI 2026 list of the world's 100 most influential people in AI field, with BABA-W (09988.HK) CEO Eddie Wu included on the annual ranking.

Others on the list include SpaceX CEO Elon Musk, OpenAI co-founder Sam Altman, ByteDance CEO Liang Rubo, Amazon.com, Inc. (AMZN.US) founder Jeff Bezos, and Anthropic co-founders Dario Amodei and Daniela Amodei.

TIME magazine said Alibaba is transforming into a global pioneer in open-source AI, having committed at least USD53 billion this year to AI and cloud infrastructure investment, and set a target of achieving annualized AI revenue of USD4.4 billion by year-end.

The magazine quoted Eddie Wu as saying that the democratization of AI will further narrow the education gap and enable fairer and more reasonable allocation of medical resources, while continuing to unleash vitality across society.
~

AASTOCKS Financial News
Website: www.aastocks.com

Information Provided by AAStocks Financial News [Disclaimer]
08:00
Luxshare Precision Reports 40.2% Revenue Growth in First Half 2026; Business Mix Supports Margin Expansion

Broad-based growth across consumer electronics, communications and data center, and automotive electronics, supported by targeted investment in AI infrastructure, intelligent vehicles and global delivery capacity

DONGGUAN, China, Aug. 28, 2026 /PRNewswire/ -- Luxshare Precision Industry Co., Ltd. ("Luxshare Precision" or the "Company") (SZSE: 002475; HKEX: 02475), a global provider of precision intelligent manufacturing solutions, today announced unaudited results for the six months ended June 30, 2026.

Revenue increased 40.2% year over year to RMB 174.50 billion, while net profit attributable to shareholders rose 18.0% to RMB 7.84 billion. Net profit attributable to shareholders excluding non-recurring gains and losses increased 6.5% to RMB 5.96 billion. Gross margin expanded by 17 basis points to 11.78%.

The margin improvement reflected operating leverage and a more diversified revenue mix, with faster growth in Communications and Data Center and Automotive Electronics, both of which carry gross margins above the Company average. Internal innovation, AI-enabled manufacturing efficiency and disciplined cost management also helped absorb pressure from foreign-exchange movements, higher input costs and investment in new businesses.

"Our first-half performance demonstrates the resilience of Luxshare Precision's diversified portfolio and global operating platform," said Wang Laichun, Chairwoman and General Manager of Luxshare Precision. "We are investing with discipline in areas supported by clear customer demand and defined technology roadmaps, particularly AI-enabled devices, AI infrastructure and intelligent vehicles. Our priorities remain execution, operating efficiency and sustainable value creation."

Strategic Investment and Financial Discipline

Research and development investment increased 43.1% to RMB 6.57 billion, primarily reflecting higher spending on engineering talent, tooling, materials and certification. More than half of the Company's R&D investment supported technology preparation for programs approaching commercialization.

Capital expenditures totaled RMB 10.27 billion, up RMB 742 million year over year, and were mainly directed toward overseas facility expansion, supporting infrastructure and new product lines. The Company prioritizes investments linked to customer programs, localized delivery and long-term manufacturing flexibility.

Inventory was RMB 50.37 billion at June 30, 2026, up 19.0% from year-end 2025, below the Company's 40.2% revenue growth. The increase primarily reflected business expansion and strategic material preparation for selected products.

First-half operating cash flow was an outflow of RMB 2.45 billion, mainly due to seasonal supplier payments and more than RMB 5 billion of strategic inventory preparation. Operating cash flow turned positive in the second quarter, reaching RMB 4.62 billion.

Foreign-exchange volatility resulted in approximately RMB 1.99 billion of losses on foreign-currency-denominated monetary assets and liabilities. Foreign-exchange risk management activities generated approximately RMB 1.30 billion in related gains. Under applicable accounting treatment, these gains were recorded as non-recurring items, while the corresponding losses remained within both disclosed net profit measures.

Growth Across Three Core Businesses

Consumer Electronics revenue increased 19.3% to RMB 122.48 billion. Luxshare Precision continued to deepen core customer relationships and strengthen its ODM and end-to-end product development capabilities. By integrating expertise across acoustics, optics, electrical systems, thermal management, magnetics and precision structures, the Company is extending its participation from components and modules to product definition, system development and volume manufacturing. Priority areas include AI PCs, smart wearables, AI glasses and intelligent acoustic products.

Communications and Data Center revenue increased 49.7% to RMB 16.61 billion. The Company is building an integrated AI infrastructure portfolio spanning high-speed copper interconnects, optical interconnects, thermal management and power management. Operational progress included volume production of 800G optical products, batch shipments of 1.6T DAC, ACC and AEC products, continued customer introductions for liquid-cooling solutions, and scaled production of DC-DC server power modules. Luxshare Precision is also advancing 224G and 448G copper technologies and next-generation optical architectures.

Automotive Electronics revenue increased 274.1% to RMB 32.39 billion, supported by organic growth, customer program ramps and Leoni's contribution. The Company continued to expand its portfolio across connectors, wiring harnesses, intelligent control systems, smart chassis technologies and powertrain solutions. High-speed connectors and rear-wheel steering products have entered mass production, while intelligent cockpit and advanced driver-assistance platforms are progressing across multiple vehicle programs. Leoni's integration continued to outperform expectations, strengthening global customer access, engineering resources and localized delivery capabilities.

Global Platform and Outlook

Luxshare Precision operates across five continents, 29 countries and more than 100 production sites. This network supports localized delivery, customer collaboration and supply chain resilience. The Company's vertically integrated platform spans precision components, functional modules and system-level products, supported by AI-enabled digital tools for quality management, predictive maintenance, production scheduling and standardized global execution.

For the remainder of 2026, Luxshare Precision will continue supporting consumer electronics product launches and ODM/JDM programs; accelerating commercialization across high-speed interconnects, optical products, liquid cooling and power management; and expanding automotive customer programs while capturing further benefits from the Leoni integration.

The Company will maintain disciplined capital allocation and continue investing in technology, manufacturing capacity and global delivery capabilities that support sustainable, high-quality growth.

About Luxshare Precision

Luxshare Precision Industry Co., Ltd. is a global provider of precision intelligent manufacturing solutions serving Consumer Electronics, Communications and Data Center, Automotive Electronics and other technology-driven industries. The Company supports customers from product definition and process development through new product introduction, volume manufacturing and global delivery.

Information Provided by PR Newswire [Disclaimer]
08:00
立訊精密2026年上半年營收同比增長40.2% 業務結構優化帶動毛利率提升

消費電子、通信與數據中心、汽車電子業務實現全面增長;公司持續佈局AI基礎設施、智能汽車領域,增強全球交付能力

中國東莞2026年8月28日 /美通社/ -- 全球精密智能製造解決方案提供商立訊精密工業股份有限公司(立訊精密」或公司」,SZSE:002475;HKEX: 02475)今天公佈了截至2026年6月30日的六個月未經審計業績。

公司營收同比增長40.2%,達到1745.0億元人民幣;歸屬於股東的淨利潤同比增長18.0%,為78.4億元人民幣;扣除非經常性損益後歸屬於股東的淨利潤同比增長6.5%,達59.6億元人民幣。毛利率提升17個基點,至11.78%。

毛利率改善源於經營槓桿效應以及收入結構多元化:通信與數據中心、汽車電子業務增速加快,兩大板塊毛利率均高於公司整體平均水平。內部技術創新、人工智能(AI)助力生產效率提升以及審慎的成本管控,也幫助公司對沖了匯率波動、原材料成本上漲以及新業務投入帶來的經營壓力。

立訊精密董事長兼總經理王來春表示:公司上半年業績,印證了立訊精密多元化業務佈局與全球化運營平台具備較強抗風險能力。我們圍繞客戶明確需求與清晰技術路線圖進行審慎投資,重點佈局AI終端設備、AI基礎設施與智能汽車賽道。公司依舊將業務落地執行、運營效率提升以及可持續價值創造作為工作重心。

戰略投資與財務管控

研發投入增長43.1%,達65.7億元人民幣,主要用於工程技術人才擴充、工裝模具、物料以及認證相關支出。公司超過半數研發資金用於即將實現商業化落地項目的技術儲備。

資本開支合計102.7億元人民幣,同比增加7.42億元,主要投向海外廠區擴建、配套基礎設施建設以及新產品產線佈局。公司投資優先匹配客戶項目需求、本地化交付以及長期製造柔性能力建設。

截至2026年6月30日,公司存貨規模503.7億元人民幣,較2025年年末增長19.0%,增幅低於公司40.2%的營收增速。存貨增長主要來自業務規模擴張以及部分產品戰略性物料儲備。

上半年經營現金流淨流出24.5億元人民幣,主要受季節性供應商款項支付、超50億元戰略性備貨投入影響。第二季度經營現金流回正,達46.2億元人民幣。

匯率波動造成外幣計價貨幣資產及負債產生約19.9億元人民幣損失;公司開展匯率風險管理業務實現約13.0億元人民幣收益。根據適用會計準則,該部分收益計入非經常性損益,而對應損失則納入兩項披露口徑的淨利潤核算範圍。

三大核心業務全線增長

消費電子業務營收1224.8億元人民幣,同比增長19.3%。立訊精密持續深化核心客戶合作,強化ODM以及端到端產品研發能力。依托聲學、光學、電氣系統、熱管理、磁學與精密結構件領域的綜合技術積累,公司業務範圍從零部件、模組進一步延伸至產品定義、系統開發以及規模化生產環節。業務重點覆蓋AI個人電腦、智能穿戴設備、AI眼鏡以及智能聲學產品。

通信與數據中心業務營收166.1億元人民幣,同比增長49.7%。公司打造覆蓋高速銅互聯、光互聯、熱管理、電源管理的一體化AI基礎設施產品矩陣。業務進展包括800G光產品實現量產;1.6T DAC、ACC、AEC產品批量出貨;液冷解決方案持續導入客戶;服務器DC-DC電源模塊規模化投產。同時,公司持續推進224G和448G銅互聯技術與下一代光架構的技術研發。

汽車電子業務營收323.9億元人民幣,同比大增274.1%,增長來源於內生業務增長、客戶項目量產以及萊尼(Leoni)並表貢獻。公司持續豐富產品矩陣,覆蓋連接器、線束、智能控制系統、智能底盤技術以及動力總成解決方案。高速連接器、後輪轉向產品已進入量產階段;智能座艙、高級駕駛輔助平台在多個整車項目穩步推進。萊尼的整合進度持續超出預期,進一步強化了公司全球客戶資源、工程研發實力與本地化交付能力。

全球化運營平台與未來展望

立訊精密業務遍佈五大洲、29個國家,擁有超100處生產基地。該網絡可保障本地化交付和客戶合作,提升供應鏈抗風險能力。公司垂直整合平台覆蓋精密零部件、功能模組和系統級產品;依托AI數字化工具,實現質量管理、預測性維護、生產排程與全球標準化運營。

展望2026年下半年,立訊精密將繼續配合消費電子產品發佈以及ODM/JDM項目落地;加快高速互聯、光模塊產品、液冷、電源管理相關業務商業化進程;拓展汽車領域客戶項目,持續釋放萊尼整合帶來的效益。

公司將繼續堅持審慎的資本配置策略,持續投入技術研發、製造產能與全球交付能力建設,推動業務實現可持續高質量增長。

關於立訊精密

立訊精密工業股份有限公司是全球精密智能製造解決方案服務商,業務覆蓋消費電子、通信與數據中心、汽車電子以及其他科技產業。公司可提供從產品定義、工藝開發,到新產品導入、規模化製造及全球交付的全鏈條服務。

Information Provided by PR Newswire [Disclaimer]